Loading…
← CockpitCompetitor Analysis › 4105.TWO TTY Biopharm Company LimitedOpen in the cockpit ↗

TTY Biopharm Company Limited4105.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Major
Momentum leader 87
Mkt cap
$615M
US dollars, full cap
Free float
88%
of shares outstanding
$/day
$2.02M
20-day average traded
Fwd P/E
10.2×
forward earnings
ROIC−WACC
+13.8 pp
WACC 5.0%
Hurdle
-17 pp
Req g minus delivered
Next earnings
119 days
17 Mar 2027
Close · TWDNT$82.40
1D-0.7%
1W+0.4%
1M-1.0%
3M+8.3%
6M+9.7%
YTD+1.1%
1Y+4.0%
ATR %1.8%
52w lowhigh5.3% off high

What TTY Biopharm does

Employees: 517

TTY Biopharm at a glance

Size TTY Biopharm (4105.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $615M, the 372nd largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$82.40 on 18 Nov 2026.

Performance Over six months the shares gained 9.7%, against -26.6% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 2nd highest of 20 in its peer set.

Growth Revenue grew 4.6% over the last twelve months (peer median +4.7%); the operating margin is 28.5% (peer median 4.2%).

Valuation It trades at 10.2× forward earnings against a peer median of 32.7× (3rd cheapest of 7).

Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -17 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 13.8 points above its cost of capital (5.0% WACC).

Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 20264105.TWO 111Peer median 75
Six months, rebased to 100: TTY Biopharm against the median of its 20 peers (local-currency closes).

TTY Biopharm financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$6.81BNT$6.45BNT$5.90BNT$5.50BNT$5.06B
Revenue growth—+9%+7%+9%—
Gross profitNT$3.88BNT$3.67BNT$3.36BNT$3.22BNT$2.96B
EBITDANT$2.15BNT$1.90BNT$1.60BNT$1.57BNT$1.41B
Net incomeNT$1.66BNT$1.56BNT$1.45BNT$1.13BNT$1.09B
Free cash flowNT$1.60BNT$1.71BNT$1.26BNT$1.07BNT$1.19B
Capital expenditureNT$383MNT$173MNT$153MNT$160MNT$181M
Total debtNT$1.86BNT$1.23BNT$1.76BNT$1.92BNT$1.87B

Quarterly statements and history in the cockpit →

TTY Biopharm competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-50%0%+50%ORCHPHARMA300194002940OLMA603567301211002793185750BCAXDBV300233ABUS300878IMMX3001474105.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. TTY Biopharm is the large dot.

Fundamentals: revenue growth against valuation

-75%-50%-25%0%+25%0×25×50×75×ORCHPHARMA6035671857503010966009763000164105.TWORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. TTY Biopharm is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-25%0%25%50%30019400294060356700279318575030023360097641233001473000164105.TWOGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. TTY Biopharm is the large dot.

TTY Biopharm competitors and peer comparison

How TTY Biopharm compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

TTY Biopharm against its 20 peers (data as of 18 Nov 2026)
Measure4105.TWOPeer medianRank in peer set
1-month return-1.0%-10.7%5th highest of 20
6-month return+9.7%-26.6%2nd highest of 20
Distance from 52-week high-5.3%-41.0%highest of 20
Revenue growth (TTM)+4.6%+4.7%8th lowest of 16
Operating margin28.5%4.2%2nd highest of 15
Forward P/E10.2×32.7×3rd cheapest of 7
Growth the price implies (Req g, 7 yrs)-8.7%9.1%least demanding of 11
Growth delivered (Del g)+8.8%+0.2%2nd highest of 11
Hurdle (Req g minus delivered)-17.5 pp+12.5 ppleast demanding of 11
ROIC minus cost of capital+13.8 pp-4.3 pphighest of 14
EV / EBITDA9.4×7.0×2nd most expensive of 4
Net debt / EBITDA-0.4×2.9×2nd least indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%10.2×-8.7%+8.8%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%83.1×n/an/a
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%n/a10.9%-5.9%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%n/a10.1%+2.1%
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a5.4×9.1%-25.1%
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%n/an/an/a
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%n/a-1.0%-17.9%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%11.4×-6.6%+5.4%
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%n/a-0.6%-1.6%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%54.0×n/an/a
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%n/an/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%6.7×-6.2%+6.5%
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%n/an/an/a
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%n/a36.3%+16.2%
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%n/a50.4%-12.3%
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%79.7×9.1%+7.9%

Questions

Which companies are TTY Biopharm's closest peers?
The cockpit's peer set: Orchid Pharma (ORCHPHARMA.NS), Fuan Pharmaceutical (Group) (300194.SZ), Zhejiang Anglikang Pharmaceutical (002940.SZ), Olema Pharmaceuticals (OLMA), HeiLongJiang ZBD Pharmaceutical (603567.SS), Hubei Biocause Heilen Pharmaceutical (301211.SZ), Achieve Life Sciences (QUIT), Luoxin Pharmaceuticals Group Stock (002793.SZ).
Is TTY Biopharm expensive compared with its peers?
On forward p/e it trades at 10.2× against a peer median of 32.7×, 3rd cheapest of 7 in its peer set. For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -17 pp: the price already allows for a slowdown.
How has TTY Biopharm stock performed?
Over six months to 18 Nov 2026 the shares returned +9.7% against -26.6% for the median peer; over one year +4.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.